Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | ALPL | P05186 | 11/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28111744 | 0.80 | ALPL (0.62) | MAPK1MAPTALPLGAARAB9A | |
| SCHEMBL171413 | 0.78 | MAPK1 (0.67) | MAPK1MAPTALPLGAARAB9A | |
| SCHEMBL285996 | 0.78 | MAPK1 (0.67) | MAPK1MAPTALPLGAARAB9A | |
| SCHEMBL68056 | 0.78 | MAPK1 (1.00) | MAPK1MAPTALPLGAARAB9A | |
| SCHEMBL20517628 | 0.77 | MAPK1 (0.65) | MAPK1MAPTALPLGAARAB9A | |
| SCHEMBL286531 | 0.77 | MAPK1 (0.65) | MAPK1MAPTALPLGAARAB9A | |
| SCHEMBL30107039 | 0.77 | MAPK1 (0.70) | MAPK1MAPTALPLGAARAB9A | |
| SCHEMBL30614240 | 0.77 | MAPK1 (0.96) | MAPK1MAPTALPLGAARAB9A | |
| SCHEMBL2631879 | 0.77 | KDM4E (0.45) | MAPK1MAPTALPLGAARAB9A | |
| SCHEMBL1812854 | 0.76 | MAPK1 (0.79) | MAPK1MAPTALPLGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024255697-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-12-19 | — | — | WO | disclosed |
| CN-113166153-B | Fused pyrazine derivatives as A2A/A2B inhibitors | 因赛特公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240360140-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2024-10-31 | — | — | US | disclosed |
| WO-2024133426-A1 | METHOD FOR CONTROLLING DIAMIDE RESISTANT PESTS AND COMPOUNDS THEREFOR | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024133426-A1 | METHOD FOR CONTROLLING DIAMIDE RESISTANT PESTS AND COMPOUNDS THEREFOR | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-27 | — | — | WO | disclosed |
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2024-06-04 | — | — | US | disclosed |
| CN-117304191-A | Fused pyrazine derivatives as A2A/A2B inhibitors | 因赛特公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20220135570-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2022-05-05 | — | — | US | disclosed |
| US-11161850-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| CN-113166153-A | Fused pyrazine derivatives as A2A/A2B inhibitors | 因赛特公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20200031835-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2020-01-30 | — | — | US | disclosed |
| CN-105555780-B | SYK inhibitors | 吉利德科学公司 | 2018-01-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135570-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | MAPK1 2389/4885MAPT 3370/4885ALPL 3843/4885 |
| US-20240360140-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | MAPK1 2389/4885MAPT 3370/4885ALPL 3843/4885 |
| US-20200031835-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | MAPK1 2389/4885MAPT 3370/4885ALPL 3843/4885 |
| US-11161850-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | MAPK1 2389/4885MAPT 3370/4885ALPL 3843/4885 |
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | MAPK1 2389/4885MAPT 3370/4885ALPL 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.